HPLC Testing for Research Peptides: A Plain-English Guide

HPLC peptide testing answers one question well: what share of the UV-detectable material in a sample is a single compound. It does not, on its own, show that the compound is the peptide named on the label, or how much peptide is in the vial. This guide explains what an HPLC purity result measures, what mass spectrometry adds, what neither test can tell you, and which report details make the phrase “HPLC tested” something you can check.

How reverse-phase HPLC separates a peptide

Most peptide purity methods use reversed-phase HPLC, also called reverse-phase HPLC or RP-HPLC, so an HPLC peptide purity figure usually comes from an RP-HPLC run. The dissolved sample is pumped through a column packed with fine particles that carry a water-repelling coating, commonly C18 hydrocarbon chains. The mobile phase starts mostly as water and becomes steadily richer in an organic solvent such as acetonitrile. Each component clings to the coating until the mobile phase can carry it off, so more hydrophobic molecules leave later, each at its own retention time.

An acidic additive, very often trifluoroacetic acid (TFA), pairs with positively charged groups on the peptide and changes how strongly it is retained. A UV detector at the column outlet records what emerges, typically at a short wavelength such as 214 nm, where the peptide bond itself absorbs. One published quality-control method for pools of synthetic peptides, for example, used a C18 column, water and acetonitrile each containing a little TFA, and UV detection at 214 nm, with a high-resolution mass spectrometer reading the same run.

The output is a chromatogram: detector signal plotted against time, with a peak for each separated component. UHPLC, also known by the trademarked name UPLC, uses smaller particles at higher pressure to give sharper peaks; our comparison of HPLC and UPLC explains what that changes for a purity result.

Reading a peptide purity result from HPLC

Area per cent

Software draws a baseline under each peak and measures its area, a step called integration. Purity is then normally reported as area per cent: the main peak’s area divided by the total area of all integrated peaks, multiplied by 100, leaving out signals from the solvent or system, such as the solvent front at the start of the run. “Purity” on a peptide report therefore means the main peak’s share of the UV signal that this method detected and integrated.

Why the detection wavelength matters

At 214 nm the peptide bond absorbs, but so do several amino-acid side chains, and aromatic residues such as tryptophan absorb more strongly than the peptide bond. Because different molecules give different signal per unit of material, an area percentage is a ratio of UV response, not strictly of weight. An impurity that absorbs weakly is under-counted, and one that barely absorbs can be missed. A 2020 study of synthetic glucagon gave related reasons why UV-based purity can be inaccurate: some impurities do not absorb ultraviolet light, and others may absorb in ways that overlap with the main constituent.

What the “main peak” means

The main peak is the largest peak and is assumed to be the target peptide; HPLC cannot confirm that on its own. A retention time that matches a reference standard is supporting evidence, not proof (relative retention time is one of the identification options in the European Medicines Agency (EMA) guideline on synthetic peptides). Anything that leaves the column at the same moment is counted inside the main peak, and closely related impurities can co-elute this way; the EMA guideline says analytical procedures should be developed with “the risk of co-eluting impurities” in mind. Our guide to reading an HPLC chromatogram explains what a shoulder and other warning signs on a trace can mean.

What the smaller peaks usually are

The smaller peaks are usually peptide-related impurities. The EMA guideline describes the main classes: deletion sequences missing one or more amino acids, insertion sequences carrying an extra one, truncated sequences, forms with side-chain protecting groups left on, diastereomers in which an amino acid has the wrong handedness, and products of oxidation or deamidation that form during manufacture or storage. Our guides to how research peptides are made and how peptides degrade explain where these impurities come from.

Why two laboratories can report different figures

Because the result depends on the column, gradient, wavelength and integration settings, two laboratories can report slightly different purities for the same material without either being wrong, so compare results from the same method where you can. In ICH Q2(R2), the guideline on validating analytical procedures for commercial drug substances and products, specificity is the extent to which other substances interfere with measuring the analyte. Where one procedure does not discriminate well enough, the guideline recommends combining two or more, and specificity can be shown by agreement with a second, well-characterized procedure that ideally uses a different measurement principle. System suitability tests verify that the measurement system and the analytical operations are fit for the intended purpose, and the harmonized chromatography chapter in USP <621> covers parameters such as resolution, peak symmetry and signal-to-noise ratio. Both were written for pharmaceutical quality control. Our explainer on analytical method validation goes further.

What mass spectrometry adds

Mass spectrometry, often shortened to mass spec, weighs molecules by turning them into ions and measuring their mass-to-charge ratio (m/z). Peptides are commonly ionized by electrospray, in which each molecule can pick up a different number of charges, so one peptide appears as a series of peaks (charge states) that software combines into a single mass. Our guide to reading a peptide mass spectrum explains charge states, isotope peaks and adducts.

The identity check is a comparison. The expected mass is calculated from the sequence (usually written in one-letter or three-letter amino acid codes), including end groups and any disulfide bridges, as our guide to peptide molecular weight shows. A clear result gives the observed and expected masses, says whether they are monoisotopic or average values, and states the difference in daltons or parts per million (ppm). Acceptance limits depend on the instrument and method; the published method mentioned above, on a high-resolution instrument, accepted identities within 5 ppm.

When the chromatograph feeds the mass spectrometer directly (LC-MS), each peak gets a mass as well as a retention time, so an impurity hidden under the main UV peak can be revealed if its mass differs; the glucagon study used LC-MS this way to tell impurities apart. Tandem mass spectrometry (MS/MS) goes further, breaking a selected ion into fragments whose masses read out the sequence. LC-MS explained covers how this works and what it cannot show.

What a matching mass does not prove

• Amino-acid order. The same amino acids in a different order give exactly the same intact mass; sequence order needs fragmentation (MS/MS) or another method.
• Leucine versus isoleucine. These two amino acids have exactly the same molecular mass, so no intact-mass measurement can tell them apart. Specialized fragmentation methods have been developed for that job.
• Mirror-image amino acids. A D-amino acid in place of the usual L-form leaves the mass unchanged (see D-amino acids explained).
• Quantity. Signal strength depends on how readily each molecule ionizes and can be suppressed by co-eluting compounds, so purity comes from the UV trace, not from mass-spectrum peak heights.

Guidance for medicines likewise does not rest identity on one technique: the EMA guideline on synthetic peptides, in effect since 1 June 2026, recommends at least two orthogonal identification methods, such as mass, relative retention time, LC-MS, peptide mapping, amino acid analysis or NMR.

HPLC vs mass spectrometry for peptides: what each test can and can’t detect

Question	HPLC with UV detection	Mass spectrometry (intact mass; LC-MS or MS/MS where noted)
What it reports	Purity as area % of the integrated UV peaks, with retention times	Observed mass, compared with the mass expected from the sequence
Purity: how much of the detected material is one compound?	Yes, under the stated method conditions	No; signal strength is not a reliable measure of amount
Identity: is the main component the right peptide?	No; a matching retention time is supporting evidence only	Strong evidence of the right composition, not proof of sequence
Impurities that separate from the main peak	Yes, if they absorb at the detection wavelength	Their masses, when coupled to a chromatograph (LC-MS)
Impurities that co-elute with the main peak	No; they are counted as part of the main peak	Often, if their mass differs (LC-MS)
Impurities that barely absorb UV light	Under-counted or missed	Seen if they ionize
Leucine versus isoleucine	May separate them; cannot say which is which without a reference	No; identical mass (specialized MS/MS needed)
Same amino acids in a different order	May separate them; cannot identify them without a reference	No by intact mass; MS/MS fragments can
D- versus L-amino acids	Only if the method resolves them	No; identical mass
Counter-ions (TFA, acetate)	No; measured separately, for example by ion chromatography	No
Water	No	No
Bacterial endotoxin	No	No
Net peptide content	No	No

In short, HPLC answers “how much of the detected material is one compound”, mass spectrometry answers “is it the right compound”, and neither weighs everything else in the vial or detects bacterial endotoxin, which needs its own assay. Guidance for medicines builds on that pairing: the U.S. Food and Drug Administration’s 2021 guidance on certain synthetic peptide generics recommends sensitive, high-resolution procedures such as UHPLC with high-resolution mass spectrometry, and identification of each peptide-related impurity present at 0.10 per cent of the drug substance or more, while the EMA guideline expects peptide-related impurities to be reported above 0.1 per cent, identified above 0.5 per cent and qualified above 1.0 per cent. Both are cited here as a benchmark for medicines, not as a statement about what applies to research reagents.

Why neither test gives net peptide content

A vial of lyophilized peptide holds more than peptide. Peptides made by solid-phase synthesis and purified by reversed-phase HPLC are typically obtained as trifluoroacetate (TFA) salts; the counter-ion can be exchanged for acetate or chloride, and the EMA guideline notes that acetate is the usual counter-ion for synthetic peptide medicines. Lyophilized powders also hold residual water. Both add weight without adding peptide, and neither appears in an HPLC purity percentage or an intact-mass result.

The gap can be large. In the glucagon study, LC-UV analysis put the purity of a synthetic glucagon sample above 970 mg/g. After measuring and subtracting everything that was not glucagon (water by Karl Fischer titration, the TFA counter-ion by ion chromatography, inorganic ions by ICP-MS, and peptide-related impurities), the mass-balance result was 896.36 ± 0.68 mg/g.

If your work depends on how much peptide is present by weight, look for a separately reported content figure. The EMA guideline lists amino acid analysis, nitrogen determination and quantitative NMR among assay methods, and expresses LC assay limits on a counter-ion-free, anhydrous basis. Our guides to net peptide content and TFA versus acetate salts and to amino acid analysis explain how those figures are produced.

What to look for on a test report

On any certificate of analysis or test report, look for:

• Laboratory, date and batch. The laboratory’s name, the test date and a batch or lot number that matches the vial (our guide to lot numbers and batch traceability explains what that number records). A document for another lot describes the product in general, not your material (see our comparison of a COA, an SDS and a specification sheet). A result also describes the material only as it was on the test date, which is where stability testing comes in.
• The method. Column type (for example C18, with particle size and dimensions), mobile phases and gradient, flow rate and detection wavelength (for example 214 nm).
• The chromatogram and integration table. The trace, with each integrated peak’s retention time, area and area %. A purity figure without a trace cannot be checked.
• A purity statement tied to the method. Area % at the stated wavelength, not a bare “purity” with no conditions.
• The mass result. Expected and observed mass, whether they are monoisotopic or average values, the difference in daltons or ppm, and the spectrum or its deconvoluted result.
• Content data, if weight matters to your work. Net peptide content, water and counter-ion results come from separate tests and appear only if those tests were run.
• Consistency. Identical-looking traces on reports for different batches, a batch number that does not match the label, or a mass claim with no spectrum are reasons to ask questions.

Our peptide COA guide covers the rest of a certificate.

Why independent testing matters

In-house results can be accurate, but a laboratory with no stake in the outcome removes one obvious conflict of interest. Independence only helps if it can be checked: the report should name the laboratory, carry the laboratory’s own report or sample number, and match the batch on the vial.

Pure Peptides Canada is a Canadian-owned supplier of research peptides based in Toronto. We list Janoshik Analytical reports for most of our products on our Lab Testing page, and reports for the rest are available on request. Our overview of research peptides in Canada explains what they are and how to verify them.

How this page fits with our other testing guides

This page is the overview; the guides linked above cover each method in more depth. For the failure modes these tests are meant to catch, see how to spot fake research peptides, and for keeping a vial in the condition its report describes, see our peptide storage guide. For the background behind the numbers, liquid chromatography explained covers how an HPLC system separates a sample, peptide purity explained covers what a purity percentage does and does not mean, and Bradford versus BCA assays compares two colorimetric protein assays and how well each works for peptides. For vials that hold more than one peptide, see what a blend’s certificate can prove.

Frequently asked questions

---

This guide is general educational information about laboratory analytical methods. Pure Peptides Canada products are supplied for laboratory research use only and are not for human or veterinary use. Nothing on this page is medical advice.

References

1. United States Pharmacopeia. Notice of Adoption of Harmonized Standard: <621> Chromatography. Posted 19 November 2021; official 1 December 2022. Confirms that the chromatography chapter was harmonized through the Pharmacopoeial Discussion Group and summarizes the changes to its provisions on resolution, peak symmetry and signal-to-noise ratio.
2. International Council for Harmonisation. ICH Q2(R2) Validation of analytical procedures. Final version, adopted 1 November 2023. Supports the descriptions of specificity, system suitability tests, combining procedures where one does not discriminate well enough, and comparison with a second procedure that ideally uses a different measurement principle, within a guideline written for commercial drug substances and products.
3. European Medicines Agency. Guideline on the development and manufacture of synthetic peptides (EMA/CHMP/CVMP/QWP/367182/2025). Adopted December 2025; in effect from 1 June 2026. Supports the impurity classes, the risk of co-eluting impurities, the recommendation of at least two orthogonal identification methods, the 0.1, 0.5 and 1.0 per cent impurity thresholds, the usual acetate counter-ion, the listed assay methods and the counter-ion-free, anhydrous basis for LC assay limits.
4. U.S. Food and Drug Administration. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin. Guidance for Industry, May 2021. Recommends orthogonal analytical methods and sensitive, high-resolution procedures such as UHPLC with high-resolution mass spectrometry, and identification of each peptide-related impurity present at 0.10 per cent of the drug substance or more.
5. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis. 2014;101:2–30. A review article on the peptide-related impurities found in peptide medicines, listed as background reading on the impurity classes described above.
6. Wang X, Zhang F, Li H, et al. Purity determination of synthetic glucagon using a mass balance approach. Scientific Reports. 2020;10:4423. Supports the reasons UV-based purity can be inaccurate, the use of LC-MS to tell impurities apart, and the LC-UV and mass-balance figures quoted for glucagon.
7. Sikora K, Jaśkiewicz M, Neubauer D, Migoń D, Kamysz W. The role of counter-ions in peptides: an overview. Pharmaceuticals. 2020;13(12):442. Supports the statements that peptides purified by reversed-phase HPLC are obtained as TFA salts, that acidic additives form ion pairs that change hydrophobicity, that counter-ions can be exchanged, and that ion chromatography is used to measure them.
8. Kuipers BJH, Gruppen H. Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm to enable quantitative reverse phase high-performance liquid chromatography-mass spectrometry analysis. Journal of Agricultural and Food Chemistry. 2007;55(14):5445–5451. Supports the statements that the peptide bond absorbs at 214 nm and that aromatic residues such as tryptophan absorb more strongly.
9. Bosc-Bierne G, Ewald S, Kreuzer OJ, Weller MG. Efficient quality control of peptide pools by UHPLC and simultaneous UV and HRMS detection. Separations. 2024;11(5):156. The published method cited for its C18 column, TFA-containing water and acetonitrile mobile phases, UV detection at 214 nm and 5 ppm mass tolerance.
10. Xiao Y, Vecchi MM, Wen D. Distinguishing between leucine and isoleucine by integrated LC-MS analysis using an Orbitrap Fusion mass spectrometer. Analytical Chemistry. 2016;88(21):10757–10766. Supports the statements that leucine and isoleucine have exactly the same molecular mass and that specialized fragmentation methods are needed to tell them apart.
11. NobelPrize.org. The Nobel Prize in Chemistry 2002: popular information. Supports the description of electrospray ionization, in which one molecule gives a series of peaks because it can take up a varying number of charges.